210 related articles for article (PubMed ID: 16140925)
1. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G
Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925
[TBL] [Abstract][Full Text] [Related]
2. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
3. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
[TBL] [Abstract][Full Text] [Related]
4. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
5. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
6. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Cuenco GM; Ren R
Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
[TBL] [Abstract][Full Text] [Related]
7. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
8. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
9. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
10. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin.
Helbling D; Mueller BU; Timchenko NA; Hagemeijer A; Jotterand M; Meyer-Monard S; Lister A; Rowley JD; Huegli B; Fey MF; Pabst T
Proc Natl Acad Sci U S A; 2004 Sep; 101(36):13312-7. PubMed ID: 15326310
[TBL] [Abstract][Full Text] [Related]
11. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
12. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
Cuenco GM; Nucifora G; Ren R
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
Mitani K
Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
[TBL] [Abstract][Full Text] [Related]
14. AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain.
Wei H; Liu X; Xiong X; Wang Y; Rao Q; Wang M; Wang J
FEBS Lett; 2008 Jun; 582(15):2167-72. PubMed ID: 18519037
[TBL] [Abstract][Full Text] [Related]
15. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
[TBL] [Abstract][Full Text] [Related]
16. Domains involved in ETO and human N-CoR interaction and ETO transcription repression.
Wang J; Wang M; Liu JM
Leuk Res; 2004 Apr; 28(4):409-14. PubMed ID: 15109542
[TBL] [Abstract][Full Text] [Related]
17. TEL2, an ETS factor expressed in human leukemia, regulates monocytic differentiation of U937 Cells and blocks the inhibitory effect of TEL1 on ras-induced cellular transformation.
Kawagoe H; Potter M; Ellis J; Grosveld GC
Cancer Res; 2004 Sep; 64(17):6091-100. PubMed ID: 15342392
[TBL] [Abstract][Full Text] [Related]
18. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.
Puccetti E; Zheng X; Brambilla D; Seshire A; Beissert T; Boehrer S; Nürnberger H; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Cancer Res; 2005 Jul; 65(14):6080-8. PubMed ID: 16024608
[TBL] [Abstract][Full Text] [Related]
19. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP.
Izutsu K; Kurokawa M; Imai Y; Ichikawa M; Asai T; Maki K; Mitani K; Hirai H
Oncogene; 2002 Apr; 21(17):2695-703. PubMed ID: 11965542
[TBL] [Abstract][Full Text] [Related]
20. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells.
Nimer SD; Moore MA
Oncogene; 2004 May; 23(24):4249-54. PubMed ID: 15156180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]